Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort
Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort
复制标题
DOI：
10.1016/j.brachy.2014.11.015
复制
发表时间：
2015-03-01
期刊：
影响因子：
1.9
通讯作者：
Guedea, Ferran
中科院分区：
文献类型：
--
作者：
Martinez, Evelyn;Daidone, Antonino;Guedea, Ferran
目得：很少有大型欧洲研究评价了永久性前列腺近距离放射治疗（PPB）作为临床局限性前列腺癌单药治疗的长期结局。本研究的目的是评估长期生存在这个patientprofile.METHODS和材料：回顾性研究的700例患者进行经会阴超声引导碘-125 PPB（145戈伊）之间的2000年1月和2012年7月。中位年龄为64.8岁（范围：35-79岁）。大多数患者（638/700; 91%）患有低风险疾病（D 'Amico标准）。85例患者（12%）接受激素治疗。使用精算和Kaplan-Meier方法计算和估计总生存期、病因特异性生存期和生化无复发生存期。组间差异进行了评估使用log-rank test.Results：中位随访时间为63个月（范围，6-164）。在5年和10年随访时，总生存率分别为94%（95%置信区间[CI]，92-96）和84%（95% CI，78-90）;病因特异性生存率分别为100%和97%（95% CI，95-99）;生化无复发生存率为95%（95% CI，93-97）和85%（95% CI，79-91）。本报告中列出的长期结果证实了先前的研究，并为PPB在高风险前列腺癌患者中的使用提供了额外的支持。种子近距离放射治疗在这种患者中提供了极好的长期结果。(C)2015年美国近距离放射治疗协会。爱思唯尔公司出版All rights reserved.
PURPOSE: Few large European studies have evaluated long-term outcomes for permanent prostate brachytherapy (PPB) as monotherapy for clinically localized prostate cancer. The objective of the present study was to evaluate long-term survival in this patient profile.METHODS AND MATERIALS: Retrospective study of 700 patients who underwent transperineal ultrasound-guided iodine-125 PPB (145 Gy) between January 2000 and July 2012. Median age was 64.8 years (range, 35-79). Most patients (638 of 700; 91%) had low-risk disease (D'Amico criteria). Eighty-five patients (12%) received hormonal treatment. Overall survival, cause-specific survival, and biochemical relapse free survival were calculated and estimated using actuarial and Kaplan-Meier methods. Differences between groups were assessed using the log-rank test.RESULTS: Median followup was 63 months (range, 6-164). At 5- and 10-year followup, respectively, overall survival was 94% (95% confidence interval [CI], 92-96) and 84% (95% CI, 78-90); cause-specific survival was 100% and 97% (95% CI, 95-99); and biochemical relapse free survival was 95% (95% CI, 93-97) and 85% (95% CI, 79-91).CONCLUSIONS: The long-term results presented in this report confirm previous studies and provide additional support for the use of PPB in patients with favorable-risk prostate cancer. Seed brachytherapy provides excellent long-term results in this patient profile. (C) 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.